Increases in VEGF and CA9 and decreases in VEGFR2 with cabozantinib treatment have been observed in triple negative breast cancer [22], and increases in VEGF, CA9, MET, and IL-8 and decreases in VEGFR2 with cabozantinib treatment have been observed in castration-resistant prostate cancer [23]. The gene discussed is VEGFA; the disease is triple-negative breast carcinoma.